Home
Categories
DMD
Research
Family Stories
Approved Treatments
Cures
About Us
Contact
Search
Home
Categories
DMD
Research
Family Stories
Approved Treatments
Cures
About Us
Contact
More
Search
ImmunoForge Receives FDA IND Approval for Phase 2 Clinical Trial of ‘Pemziviptadil’ for DMD Cardiomyopathy
Research
DMD Warrior
-
A medication for DMD cardiomyopathy, pemziviptadil is used once a week and is based on ImmunForge's ELP Platform (Elastin...
Sarepta Reiterated Total Net Product Revenue of $3.0 Billion in 2025
DMD
DMD Warrior
-
As children and families battling Duchenne Muscular Dystrophy wait for drug prices to drop, Sarepta has announced its earnings...
Wave Life Sciences Announces Plans for Exon 53 Skipping Study in 2025
DMD
DMD Warrior
-
Alpha-1 antitrypsin deficiency (AATD), Huntington's disease (HD), obesity, and Duchenne muscular dystrophy (DMD) are among the major unmet medical...
Edgewise Therapeutics Announces Plans for 2025
DMD
DMD Warrior
-
Vamorolone (Agamree) Approved in Scotland
Approved Treatments
DMD Warrior
-
Nutrition Guideline for Duchenne Muscular Dystrophy: Foods to Eat and Avoid
DMD
DMD Warrior
-
Plans for DYNE-101 in DM1 and DYNE-251 in DMD Are Announced by Dyne Therapeutics
Research
DMD Warrior
-
Load more